latest news releases from the newsroom
TASER International, Inc.
14th Product Liability Lawsuit Dismissed Against TASER International
SCOTTSDALE, Ariz., May 2, 2006 (PRIMEZONE) -- TASER International, Inc. (Nasdaq:TASR), a market leader in advanced electronic control devices announced that the U.S. District Court for the Southern District of Florida, Miami Division, entered a judgment of dismissal ordering the dismissal with prejudice of the product liability lawsuit filed by Salvatore Dimiceli against TASER International, Inc. This is the fourteenth wrongful death or injury lawsuit that has been dismissed or judgment entered in favor of TASER International in the past 24 months.
ATSI Communications, Inc.
ATSI's Revenues Increase 128 Percent
SAN ANTONIO, May 2, 2006 (PRIMEZONE) -- ATSI Communications, Inc. (OTCBB:ATSX) announced today that the Company's revenues for the three months ended April 30, 2006 reached a record high of $4,098,000 that included peak monthly revenue of over $1,600,000 for the month of April 2006. As a result, the Company expects to report its 7th consecutive quarter of record revenues since its reincorporation with an increase of 128% over the previous fiscal year's 3rd quarter ended April 30, 2005. The Company also reported that revenue for the three months ended April 30, 2006 exceeded revenue for the immediately preceding quarter ended January 31, 2006 by $1.1 million.
SecureLogic Settles Lawsuit
NEW YORK, May 2, 2006 (PRIMEZONE) -- SecureLogic (OTCBB:SLGI) (the "Company") announced today that it has completed a settlement in its lawsuit against Vinci Airports US, Inc. ("Vinci"). The lawsuit was originally filed by the Company's SpaceLogic, Ltd. subsidiary in 2002 in the Federal District Court for the Southern District of New York.
Genesis Pharmaceuticals Enterprises, Inc.
Genesis Releases Quarterly Report Revealing Profitability with $1.75 Million Gain in 'Historic Turnaround'
BOCA RATON, Fla., May 2, 2006 (PRIMEZONE) -- Genesis Technology Group, Inc. (OTCBB:GTEC) has released its 10-QSB for the second quarter of the current fiscal year. For the quarter ended March 31, 2006, the Company's net income exceeded $500,000, while overhead plummeted by 54% percent. Additionally, the Company has reached an enviable cash position with approximately $1.9 million on hand. Company Chief Financial Officer Adam Wasserman called "the first profitable quarter in the history of Genesis...an impressive, historic turnaround by any standards."
Jerini Appoints Andrew D. Curtis as Vice President U.S. Marketing for Jerini U.S., Inc.
BERLIN, May 2, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced the appointment of Andrew D. Curtis as Vice President U.S. Marketing, effective May 1, 2006. Curtis will be heading Jerini's recently established subsidiary, Jerini U.S., Inc., headquartered in the New York metropolitan area. "We are extremely pleased to welcome Andrew to Jerini's team," said Jens Schneider-Mergener, CEO of Jerini. "His extensive marketing and business development experience are vital for this key position, allowing Jerini to strengthen and expand our U.S. presence. Jerini U.S. will also work closely with our U.S. partner, Kos Pharmaceuticals, Inc., to coordinate the planned North American market launch of our lead product, Icatibant, for hereditary angioedema in 2007."